Victoria's Secret stock surges nearly 300% as GLP-1 weight-loss drugs influence lingerie buying habits
Victoria’s Secret shares have surged almost 300% over the past year, trading under a new ticker symbol VSXY since June 2026. The rise is attributed to stronger sales, brand revitalization, and improved leadership, but analysts also highlight an unexpected factor: GLP-1 weight-loss drugs like Ozempic are reshaping consumer behavior in the lingerie market. As users of these medications lose significant amounts of weight, they often need to replace clothing that no longer fits. This has led to increased demand for new bras and underwear, benefiting retailers such as Victoria’s Secret. The company reported a 3% shift downward in bra sizes purchased, which CEO Hillary Super linked directly to the impact of GLP-1 drugs. Beyond this trend, Victoria's Secret is experiencing broader business improvements under its current leadership. In Q1 fiscal year 2026, sales rose by 15%, with comparable store sales up 13% and operating income increasing from $20 million to $76 million.
Topics: consumer behavior GLP-1 drugs Ozempic effect Victoria's Secret